Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

THE TRUTH ABOUT: Urogen pharma s return on capital employed overview | History Defined

According to data from Benzinga Pro, during Q4, UroGen Pharma's (NASDAQ:URGN) reported sales totaled $16.17 million. Despite a 5.82% increase in earnings, the company posted a loss of $28.45 million. UroGen Pharma collected $11.35 million in revenue during Q3, but reported earnings showed a $30.21 million loss.

What Is ROCE?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.